Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurence of cholelithiasis

Elio Roti, R. Minelli, E. Gardini, M. Salvi, L. Bianconi, L. Balducci, A. Manfredi, L. E. Braverman

Research output: Contribution to journalArticlepeer-review

Abstract

The long-acting somatostatin analogue SMS 201-995 has been used efficaciously in the therapy of metastatic carcinoid tumor, vasoactive intestinal peptide producing islet cell carcinoma, acromegaly, and TSH secreting pituitary tumors. We report the development of a gallstone in a patient treated for 23 months with a long acting somatostatin analogue for a metastatic carcinoid tumor. Symptomatic improvement and a reduction in the urinary excretion of 5-hydroxyin-doleacetic acid occurred. There was no evidence of a gallstone on ultrasound and CT scan of the abdomen prior to somatostatin therapy. A progressively enlarging, asymptomatic gallstone developed during therapy.

Original languageEnglish
Pages (from-to)69-72
Number of pages4
JournalJournal of Endocrinological Investigation
Volume13
Issue number1
DOIs
Publication statusPublished - 1990

Keywords

  • Carcinoid tumor
  • cholelithiasis
  • SMS 201-995

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurence of cholelithiasis'. Together they form a unique fingerprint.

Cite this